Quarterly report (Form 10-Q)
Bristol Myers Squibb 10-Q for Quarter ended Mar 31, 2026
Filing excerpt
Announced FDA approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL.